A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > REGULATORY
REGULATORY
- Industry Representatives Express Concern over Large Reductions in Prices of Long-Listed Drugs at CSIMC
July 20, 2012
- Industry Figures Stress Positive Impact of Premium for Generic-Name Prescribing at CSIMC
July 20, 2012
- Cost-Effective Assessments to Be Limited to Technologies for Which Alternatives Are Available: CSIMC
July 19, 2012
- PAFSC’s 2nd Committee on Drugs to Review 2 Combination DPT-IPV Vaccines on July 20
July 19, 2012
- Establishment of Relief System for Victims of Health Damage Due to Anticancer Drugs Should Be Put Off: MHLW Study Group
July 17, 2012
- Draft Revitalization Strategy Calls for Screening of 100 Drug Seeds through Drug Discovery Support Network by FY2015
July 13, 2012
- PFSB Calls for Revisions of Package Inserts for 13 Products Including Ranmark, Lyrica
July 13, 2012
- Gov’t to Discuss Expansion of Japan-EC Mutual Recognition Agreement in Pharmaceutical Sector
July 12, 2012
- Health Minister Komiyama Takes Lead to Include Reference Price Systems in Policy-Screening Group’s Proposals
July 10, 2012
- MHLW’s Medical Innovation Promotion Office Sets Up Cross-Sectional Task Forces to Discover Innovative Anticancer Drugs
July 10, 2012
- Bill Payers, Healthcare Providers Fighting over Financial Resources from Price Cuts for Long-listed Drugs
July 10, 2012
- PAFSC Second Committee to Review Products Including Novartis’s Pulmonary Infection Treatment on July 20
July 10, 2012
- Council’s Action Plan for FY2013 Calls for Conducting 10 Kinds of Clinical Trials within 5 Years
July 9, 2012
- On-Site Strategy Consultations to Be Held in Kansai Region: MHLW
July 6, 2012
- Interest Shown in Development of 3 Unapproved Drugs/Indications Including Metyrosine
July 6, 2012
- PMDA to Use Science Committee to Help Strengthen Review System: Executive Director Utsumi
July 5, 2012
- MHLW Approves 2 APIs Including Switch OTC Version of Allegra
July 5, 2012
- New Bar Code Labeling Rules to Take Effect for Oral, Topical Drugs from July 2015
July 3, 2012
- 18 Ethical APIs/35 Products Reported at PAC
July 3, 2012
- MHLW Approves 15 Products Including Inlyta and Tenelia
July 2, 2012
ページ
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…